Newscast – Page 76 – media

Attacking the common cold by unshielding its genome

The problem with the common cold is that it isn’t just one virus. It’s a family of viruses that evolve so quickly no one can ever be fully immune to the cold, and developing a vaccine that can tackle all of the variations of the virus is impossible. But what if there were one way to block the ability of all cold viruses from replicating—thereby fending off the sneezing, sore throat and general misery that they cause?
- Source: FierceBiotech
- 578
- May 16, 2018
common cold genome Researches
Feds join lawsuits claiming Insys used strip club visits, super-doses and more to boost Subsys sales

Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who've detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller.
- Source: FiercePharma
- 682
- May 16, 2018
Company Insight lawsuit pharma
U.S. healthcare to be disrupted through a low-cost health network

As America’s population ages, a 4 billion USD opportunity is being foreseen by Thomas DeRosa for changing the U.S. health infrastructure through instituting a low-cost healthcare network and disrupting conventional healthcare practices.
- Source: Ddu
- 640
- May 16, 2018
healthcare Market Views
Plans unveiled by FDA for augmenting competition in drug markets

With the unveiling of a new drug price plan by the Trump Administration, the Food and Drug Administration (FDA) will put into action a plan to infuse competition in drug markets.
- Source: Ddu
- 378
- May 16, 2018
Security issues with Philips, GE, and Silex medical devices

Serious security flaws were discovered in Philips, GE and Silex medical devices that, if exploited, could allow authorized access and let a hacker obtain elevated privileges, according to two separate U.S. Department of Homeland Security ICS-CERT alerts issued this month.
- Source: HealthIT news
- 655
- May 15, 2018
Company Insights cybersecurity medical device
Integration of next-generation sequencing data in clinical trials facilitated by DNAnexus

A clinical trial solution has been unveiled by DNAnexus that facilitates the integration of genomics data sourced from next-generation sequencing (NGS) into clinical studies. A cloud-based genomic data collection platform is offered by DNAnexus.
- Source: Ddu
- 570
- May 15, 2018
Company Insights digital health
Qventus raised $30M investment from Bessemer Venture Partners

Mountain View, California startup - Qventus a healthcare management tech platform which uses artificial intelligence to improve hospital workflow, closed at $30 million in series B funding which will be used to expand its platform. The funding was led by Bessemer Venture Partners along with few other participants. Including this latest funding, Qventus bagged total $43 million.
- Source: Ddu
- 552
- May 15, 2018
AI Company Insights digital health
Huge biologics plant planned to be built by Sinobioway Biomedicine

Plans are afoot at Shandong Sinobioway Biomedicine Co. in China to construct a huge biologics plant as the country moves towards cell-based drugs.
- Source: drugdu
- 882
- May 15, 2018
biopharmaceutical China Market Views
Personalized Cancer Vaccine Looks Promising in Early Study

Researchers at the Perelman School of Medicine and the Abramson Cancer Center, at the University of Pennsylvania, developed the vaccine using dendritic cells (DCs) derived from each patient's own peripheral blood mononuclear cells. These dendritic cells were then exposed to the patient's tumor cells, activated with interferon gamma, and injected into the patient's lymph nodes.
- Source: Clinical Advisor
- 676
- May 15, 2018
anti-cancer cancer Researches
Ascletis files for Hong Kong IPO as floodgates open to prerevenue biotechs

Ascletis Pharma has become the first company to seek to list (PDF) in Hong Kong under the exchange’s new, more relaxed rules on biotech IPOs. The antiviral disease specialist will use the cash to win approvals for hepatitis C drugs licensed from Roche and Presidio Pharmaceuticals.
- Source: Fierce Pharma
- 891
- May 14, 2018
Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.